| scholarly article | Q13442814 |
| P356 | DOI | 10.1080/17512433.2016.1209111 |
| P698 | PubMed publication ID | 27373318 |
| P50 | author | Roberto Coccurello | Q56943906 |
| P2093 | author name string | T Bisogno | |
| P2860 | cites work | Functional organization of the basal ganglia: Therapeutic implications for Parkinson's disease | Q22252880 |
| PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats | Q24681458 | ||
| Neuroinflammation in Parkinson's disease and its potential as therapeutic target | Q26783305 | ||
| Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes | Q28189644 | ||
| Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets | Q28203208 | ||
| Normal huntingtin function: an alternative approach to Huntington's disease | Q28281904 | ||
| Adenosine-cannabinoid receptor interactions. Implications for striatal function | Q28286488 | ||
| In vitro and in vivo models of Huntington's disease show alterations in the endocannabinoid system | Q28570135 | ||
| Striatal adenosine A2A and cannabinoid CB1 receptors form functional heteromeric complexes that mediate the motor effects of cannabinoids | Q28571785 | ||
| Non-CB1, non-CB2 receptors for endocannabinoids, plant cannabinoids, and synthetic cannabimimetics: focus on G-protein-coupled receptors and transient receptor potential channels | Q33348081 | ||
| A restricted population of CB1 cannabinoid receptors with neuroprotective activity | Q33730578 | ||
| Protective effects of the synthetic cannabinoids CP55,940 and JWH-015 on rat brain mitochondria upon paraquat exposure | Q34118397 | ||
| Type 1 cannabinoid receptor ligands display functional selectivity in a cell culture model of striatal medium spiny projection neurons | Q34138944 | ||
| Neuroprotective properties of cannabigerol in Huntington's disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice. | Q34440282 | ||
| Circuits and circuit disorders of the basal ganglia | Q34599488 | ||
| Functional significance of the cortico-subthalamo-pallidal 'hyperdirect' pathway | Q34688620 | ||
| Presynaptic adenosine A2A receptors dampen cannabinoid CB1 receptor-mediated inhibition of corticostriatal glutamatergic transmission | Q35039222 | ||
| The therapeutic potential of cannabinoids for movement disorders | Q35171113 | ||
| Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ⁹-THCV in animal models of Parkinson's disease | Q35193305 | ||
| Huntington's Disease and Striatal Signaling. | Q35286098 | ||
| The Basal Ganglia and involuntary movements: impaired inhibition of competing motor patterns | Q35564115 | ||
| The cannabinoid agonist WIN55212-2 decreases L-DOPA-induced PKA activation and dyskinetic behavior in 6-OHDA-treated rats | Q35740152 | ||
| The endocannabinoid system and its therapeutic exploitation | Q35876026 | ||
| CB₂: therapeutic target-in-waiting | Q35936413 | ||
| Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors. | Q36248857 | ||
| Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease. | Q37253331 | ||
| WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. | Q37371387 | ||
| The inhibition of 2-arachidonoyl-glycerol (2-AG) biosynthesis, rather than enhancing striatal damage, protects striatal neurons from malonate-induced death: a potential role of cyclooxygenase-2-dependent metabolism of 2-AG. | Q37577451 | ||
| Dopamine and synaptic plasticity in dorsal striatal circuits controlling action selection | Q37629163 | ||
| Homeostatic changes of the endocannabinoid system in Parkinson's disease | Q37853933 | ||
| Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? | Q38012845 | ||
| The endocannabinoid system and the brain | Q38026949 | ||
| Endocannabinoids, related compounds and their metabolic routes. | Q38262964 | ||
| A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington's disease. | Q38392800 | ||
| Cannabinoids increase type 1 cannabinoid receptor expression in a cell culture model of striatal neurons: implications for Huntington's disease. | Q51057819 | ||
| Biased Agonism and Biased Allosteric Modulation at the CB1 Cannabinoid Receptor. | Q51742695 | ||
| The Endocannabinoid System and its Modulation by Phytocannabinoids | Q38566339 | ||
| Distribution of the Endocannabinoid System in the Central Nervous System | Q38593117 | ||
| Endocannabinoids and Neurodegenerative Disorders: Parkinson's Disease, Huntington's Chorea, Alzheimer's Disease, and Others | Q38593124 | ||
| An Introduction to the Endogenous Cannabinoid System | Q38677365 | ||
| New and emerging medical therapies in Parkinson's disease | Q38718194 | ||
| Biased Type 1 Cannabinoid Receptor Signaling Influences Neuronal Viability in a Cell Culture Model of Huntington Disease | Q38809361 | ||
| Cannabinoids inhibit cellular respiration of human oral cancer cells | Q39697650 | ||
| Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia. | Q39801798 | ||
| Severe deficiency of the fatty acid amide hydrolase (FAAH) activity segregates with the Huntington's disease mutation in peripheral lymphocytes. | Q40205916 | ||
| Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease | Q40358139 | ||
| Identification of CB₂ receptors in human nigral neurons that degenerate in Parkinson's disease. | Q41720746 | ||
| Balancing the basal ganglia circuitry: a possible new role for dopamine D2 receptors in health and disease | Q41878026 | ||
| Dynamic changes of anandamide in the cerebrospinal fluid of Parkinson's disease patients | Q42167232 | ||
| Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease | Q42455405 | ||
| Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease. | Q42478056 | ||
| Unilateral 6-hydroxydopamine lesions of nigrostriatal dopaminergic neurons increased CB1 receptor mRNA levels in the caudate-putamen | Q42487505 | ||
| Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington's disease mice | Q42490465 | ||
| Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models | Q42508054 | ||
| Expression and function of CB1 receptor in the rat striatum: localization and effects on D1 and D2 dopamine receptor-mediated motor behaviors. | Q42520647 | ||
| Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: in vivo and in vitro evidence. | Q42624110 | ||
| The effects of cannabinoid drugs on abnormal involuntary movements in dyskinetic and non-dyskinetic 6-hydroxydopamine lesioned rats | Q42871461 | ||
| Behavioural and molecular consequences of chronic cannabinoid treatment in Huntington's disease transgenic mice. | Q42988084 | ||
| A pilot study using nabilone for symptomatic treatment in Huntington's disease | Q43257764 | ||
| Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity. | Q43266820 | ||
| Enhanced striatal glutamate release after the administration of rimonabant to 6-hydroxydopamine-lesioned rats | Q43425029 | ||
| Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease | Q43504648 | ||
| Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington's disease | Q43669613 | ||
| Cannabinoid receptor agonist and antagonist effects on motor function in normal and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-treated non-human primates. | Q43683165 | ||
| Effects of cannabinoids in the rat model of Huntington's disease generated by an intrastriatal injection of malonate | Q44511287 | ||
| Regional changes in type 1 cannabinoid receptor availability in Parkinson's disease in vivo | Q44641132 | ||
| Potential involvement of cannabinoid receptors in 3-nitropropionic acid toxicity in vivo. | Q45217300 | ||
| L-DOPA disrupts adenosine A(2A)-cannabinoid CB(1)-dopamine D(2) receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: biochemical and behavioral studies | Q45228276 | ||
| CNR1 variation is associated with the age at onset in Huntington disease | Q45293518 | ||
| UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders. | Q45297533 | ||
| Widespread decrease of type 1 cannabinoid receptor availability in Huntington disease in vivo | Q45299326 | ||
| The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease | Q45300428 | ||
| The cannabinoid receptor agonist WIN 55,212-2 attenuates the effects induced by quinolinic acid in the rat striatum. | Q45302088 | ||
| The Hdh(Q150/Q150) knock-in mouse model of HD and the R6/2 exon 1 model develop comparable and widespread molecular phenotypes | Q45304409 | ||
| Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6/2 mice, a transgenic model of Huntington's disease | Q45305788 | ||
| Marked differences in neurochemistry and aggregates despite similar behavioural and neuropathological features of Huntington disease in the full-length BACHD and YAC128 mice | Q45306356 | ||
| Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism | Q45310537 | ||
| The CB(1) antagonist rimonabant is adjunctively therapeutic as well as monotherapeutic in an animal model of Parkinson's disease. | Q46026291 | ||
| High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients. | Q46456086 | ||
| Differential upregulation of the cannabinoid CB₂ receptor in neurotoxic and inflammation-driven rat models of Parkinson's disease | Q48219185 | ||
| Potential of the cannabinoid CB(2) receptor as a pharmacological target against inflammation in Parkinson's disease | Q48235219 | ||
| Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties | Q48324018 | ||
| Cannabinoid-induced changes in respiration of brain mitochondria. | Q48559854 | ||
| Mitochondrial CB₁ receptors regulate neuronal energy metabolism | Q48629492 | ||
| L-DOPA-treatment in primates disrupts the expression of A(2A) adenosine-CB(1) cannabinoid-D(2) dopamine receptor heteromers in the caudate nucleus | Q48873583 | ||
| The combination of oral L-DOPA/rimonabant for effective dyskinesia treatment and cytological preservation in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia | Q48890770 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cannabinoids | Q422936 |
| P304 | page(s) | 1351-1362 | |
| P577 | publication date | 2016-07-19 | |
| P1433 | published in | Expert Review of Clinical Pharmacology | Q15793519 |
| P1476 | title | The bright side of psychoactive substances: cannabinoid-based drugs in motor diseases | |
| P478 | volume | 9 |
Search more.